What Medify Photobiomodulation does

Medify Photobiomodulation, operating as Medify, Inc., is a privately held consumer and medical device company headquartered in Marina Del Rey, California, founded in 2020. The company designs, manufactures, and sells transcranial photobiomodulation (tPBM) headsets under the Titan-iR and Titan-iR Pro brands, using specific wavelengths of light (630nm-900nm and 900nm-1100nm in the Pro model) intended to stimulate mitochondrial activity and neural ion channels in the brain. Its core technology platform, branded Advanced Spectrum Biotherapeutics, is positioned for cognitive wellness and performance rather than as a treatment for specific medical conditions.

The company offers two hardware SKUs: the Titan-iR consumer headset at $1,899 sold direct-to-consumer via medifypbm.com, and the Titan-iR Pro clinical-grade headset at $2,499 distributed exclusively through authorized Medify Healthcare Providers, including a dedicated TMS provider integration program. A companion mobile application (available on Android, with iOS in development) delivers structured protocol sessions and longitudinal cognitive performance tracking, and the Medify Neurosuite platform provides clinical-grade cognitive metrics for healthcare providers. The company supports several consumer and clinical use cases including focus, mental clarity, post-TMS maintenance, and adjunct therapy, and ships to the United States, United Kingdom, and most of the European Union.

The business model is hardware-led one-time sales with no disclosed subscription or consumables stream, supported by a hybrid go-to-market approach combining direct e-commerce, an authorized healthcare provider network, mobile app distribution through app stores, and content-led demand generation. The company is small (1-10 employees), has not disclosed any external funding, and serves a horizontal mix of customer segments spanning everyday consumers, professionals, athletes, students, longevity-focused users, and clinical providers.

Name

Medify Photobiomodulation

Legal name

Medify, Inc.

Website

https://medifypbm.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Medify Photobiomodulation is a Marina Del Rey-based private medical device company that designs and sells transcranial photobiomodulation headsets (Titan-iR and Titan-iR Pro) for cognitive wellness, targeting both individual consumers via e-commerce and healthcare providers, including TMS clinics, through an authorized provider channel.

Ownership category

akta.pro rank

Headquarters

HQ city

Marina Del Rey

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Titan-iR Device Sales: One-time hardware purchase of Titan-iR consumer device at $1,899. Direct-to-consumer e-commerce sales through company website.
2. Titan-iR Pro Device Sales: One-time hardware purchase of Titan-iR Pro professional device at $2,499. Available only through authorized Medify Healthcare Providers with approved checkout code.
3. Mobile Application: Companion mobile app for device control, cognitive performance monitoring, and protocol access. Available on Android; iOS version in development.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

Core offering

Medify Photobiomodulation designs, develops, and manufactures transcranial photobiomodulation (tPBM) headsets that deliver specific wavelengths of light to stimulate brain cellular activity. The company sells the consumer-grade Titan-iR headset and the clinical-grade Titan-iR Pro headset, paired with a companion mobile application delivering protocol-based cognitive sessions.

Product overview

Medify Photobiomodulation offers a platform-plus-products architecture centered on transcranial photobiomodulation (tPBM) technology for brain health and cognitive enhancement. The core consumer product is the Titan-iR® Advanced Biotherapeutic Headset ($1,899), which utilizes validated therapeutic wavelengths for improved cognitive function. The professional-tier Titan-iR Pro® ($2,499) elevates the offering with dual biotherapeutic windows (630nm-900nm ATP optimization and 900nm-1100nm Light-Gated Ion Channel activation) for clinical-grade treatments. The Titan-iR Mobile Application serves as a companion app providing protocol-based sessions, performance tracking, and personalized cognitive programs. Medify Neurosuite provides clinical-grade cognitive metrics and analytics for healthcare providers. The product line targets both consumer self-care and professional clinical use, with protocols ranging from beginner to advanced/max levels.

Differentiator

Problem solved

Functional benefit

Brands

• Titan-iR: Advanced Spectrum Biotherapeutics device designed to boost cognitive resources, enhance mental acuity, decision-making, and cognitive performance through transcranial photobiomodulation.
• Titan-iR Pro
• Medify Neurosuite

Products and services

• Titan-iR® Advanced Biotherapeutic Headset Consumer-grade transcranial photobiomodulation headset priced at $1,899, designed to enhance mood, focus, and productivity using a single therapeutic window of validated wavelengths. Targeted at individual consumers seeking non-invasive cognitive wellness.
• Titan-iR Pro® Advanced + Deep Spectrum Biotherapeutic Headset Clinical-grade dual-spectrum biotherapeutic headset priced at $2,499, featuring dual therapeutic windows (630nm-900nm and 900nm-1100nm) for deeper, more comprehensive brain stimulation. Sold exclusively through authorized healthcare providers for in-clinic or supervised home use.
• Titan-iR Mobile Application Companion mobile application that controls the Titan-iR device, delivers tiered protocol sessions (Beginner, Intermediate, Advanced, Max, Open), and tracks cognitive performance over time. Available on Android via Google Play and on iOS via the Apple App Store.
• Medify Neurosuite Clinical-grade cognitive performance metrics and analytics platform that delivers personalized insights to track and empower greater cognitive improvements. Designed for healthcare providers and clinical use cases.

Quantifiable outcome

• 9% improvement in brain processing speed (P300 latency) after single session
• +12 more outcomes

Named customers5 records

Segments8 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators17 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Neuronetics: Neuronetics markets the FDA-cleared NeuroStar TMS system for depression and is the dominant transcranial stimulation incumbent that Medify explicitly positions Titan-iR Pro as an adjunct to in TMS facilities.
• BrainsWay: BrainsWay develops deep transcranial magnetic stimulation systems for mental health and neurological conditions, representing the larger, FDA-cleared incumbent that TMS providers integrate Titan-iR Pro alongside.
• Magstim: Magstim supplies TMS equipment and research-grade transcranial stimulators globally, competing for the same clinician budgets and TMS facility integration slots that Medify targets with Titan-iR Pro.

Emerging players

• Sooma Medical: Sooma Medical manufactures transcranial direct current stimulation devices for depression and pain used in clinics, representing an emerging non-invasive neuromodulation player Medify competes against for clinician budgets.
• Omnipathology Medical / Neuronic Devices: Neuronic Devices is an emerging player developing transcranial photobiomodulation devices for cognitive health, directly competing with Titan-iR in the at-home consumer brain stimulation niche.
• Cervel Neurotech: Cervel Neurotech develops transcranial direct current stimulation systems for clinical and research applications, positioning as an emerging non-invasive neuromodulation peer with overlapping clinician customers.
• NeuroField: NeuroField produces low-intensity transcranial stimulation and neurofeedback devices used in clinical practices, representing an emerging neuromodulation peer targeting similar clinician customers with adjacent modalities.

Direct peers

• Vielight: Vielight is the most established direct competitor in transcranial photobiomodulation, selling consumer and clinical-grade intranasal plus headset PBM devices targeting the same cognitive performance, brain health, and wellness use cases as Medify's Titan-iR line.
• THOR Photomedicine: THOR Photomedicine is a leading photobiomodulation device manufacturer with neurological and cognitive applications, supplying both clinical and research-grade PBM systems that overlap with Titan-iR Pro's wavelength and indication footprint.
• LiteCure / LCT Medical: LiteCure manufactures medical-grade light therapy devices including transcranial PBM systems, competing head-to-head with Titan-iR Pro in the clinician channel and overlapping in cognitive and neurological indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/medifypbm
• Facebookfacebook.com/medifypbm
• Instagraminstagram.com/medifypbm
• LinkedInlinkedin.com/company/medifybio

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medify Photobiomodulation